Search

everythinglearnresearchcommunity

for

Search:↓

RU58841, Minoxidil, and finasteride are discussed as treatments for hair loss. Users share experiences and results with these treatments.

The conversation is about the safety of Breezula compared to RU58841 for hair loss treatment. The user believes Breezula is safer but less effective than RU58841.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, RU58841, and Xeljanz. The user inquires about Xeljanz and shares a link suggesting it may help with hair loss.

How diffuse unpatterned alopecia (DUPA) is not an invitation to self-diagnose oneself with aggressive AGA and that seeking a specialized dermatologist may help people experiencing hair loss. Treatment options discussed include topical clobetasol propionate, oral minoxidil, and discontinuing finasteride.

A 33-year-old male is seeking advice on reversing grey hair while using minoxidil, finasteride, ketoconazole, derma rolling, cold baths, and leg exercises for hair loss. Another user mentions hearing about GHK-Cu for grey hair reversal.

A 29-year-old is using oral minoxidil, finasteride, hormone replacement therapy (HRT), and microneedling for hair regrowth. They started balding at 20, worsened at 25, and are transitioning with testosterone blockers.

The user is hesitant to use finasteride due to potential hormonal side effects and is waiting for the release of pyrilutamide, a new hair loss treatment. Other users suggest trying finasteride, warning about potential regret if hair loss progresses in the meantime.

GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.

The post discusses a product from Hims that combines finasteride, minoxidil, and biotin in one pill for hair loss. Users share mixed opinions, with one praising its effectiveness, while another warns against potential heart-related side effects of oral minoxidil, suggesting topical solutions instead.

A person shared their hair regrowth journey using HIMS topical treatments with finasteride, minoxidil, hormone replacement therapy (HRT), and microneedling. They also discussed their transition as a transgender woman and the positive impact of HRT on hair recovery.

Diffuse thinners find shopping challenging due to harsh overhead lighting, but H&M's side lighting in fitting rooms is more flattering. Many users humorously suggest banning overhead lighting to improve the shopping experience.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The user experienced noticeable hair regrowth using topical minoxidil and a dermaroller within a month. They are advised to consider DHT inhibition for lasting results.

The conversation humorously discusses the exaggerated effects of taking a 500mg pill of dutasteride, with users joking about extreme side effects like excessive hair growth and loss of sensation. It also mentions personal experiences with finasteride and the potential high bioavailability of dutasteride in liquid form.

Making a hair solution using RU58841 from raw powder. Users humorously compare the process to a science experiment.

RU58841, a potential hair loss treatment, was not commercialized due to marketability issues and lack of long-term safety data. Concerns about its formulation and delivery methods further complicate its use.

RU58841 powder may degrade over time, even when stored in a freezer. Users discuss its potential effectiveness after three years of storage.

A 28-year-old male is experiencing excessive hair shedding despite using oral and topical minoxidil, and occasionally using ketoconazole shampoo. He is considering trying GHK-Cu serums but cannot use finasteride.

People discuss adding RU58841 to their hair loss treatment, which includes dutasteride and minoxidil. Experiences vary, with some reporting positive results and others experiencing no benefits or side effects.

Kirkland Minoxidil typically contains 50-60% propylene glycol. Users suggest adjusting the percentage for sensitive skin.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841, and highlights hair multiplication research from Koehler Lab at Harvard. Users express optimism about future advancements.

A user has been taking finasteride for 5 months with no improvement in diffuse hair loss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.

The user plans to switch to oral finasteride and oral minoxidil due to insufficient results from PRP, topical minoxidil, and mild DHT inhibitors. They seek advice on purchasing these medications from My.India, questioning its trustworthiness.

The user has been using dutasteride, RU58841, and minoxidil for hair loss, experiencing some side effects and mixed results, with RU58841 notably reducing scalp itch. Despite extensive treatment, the user has maintained hair but struggles with hairline thickening.

Cetirizine 10mg daily reduced hair shedding by 50% and lessened scalp itchiness. The user is considering long-term use for scalp inflammation and hair loss.

The conversation discusses using azelaic acid to reduce scalp inflammation while using RU58841 for hair loss. It suggests applying azelaic acid in the morning and RU58841 at night to avoid degradation, while also using dutasteride and minoxidil.

The user is experiencing diffuse androgenic alopecia and is trying various treatments, including 5mg finasteride, loniten, and Formula 82D, which contains dutasteride, a steroid, and tretinoin. They report potential regrowth with Formula 82D, despite previous treatments being ineffective.

A user hopes to regrow hair using a routine of Min/fin solution twice daily, dermarolling twice weekly, multivitamins daily, and biotin twice daily. Another user doubts the effectiveness of biotin and multivitamins.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.